Techniclone (TCLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Terry D. who wrote (2595)	10/5/1998 5:22:00 PM
From: shero	Read Replies (2) of 3702

Including prostate cancer in the latest clinicals won't mean anything to Milken. Results will. but the answer to your question is yes. However the results of the PAACT study were public years ago and they were made available to the Milken group. To no avail. My point is only results in present and future trials will make a difference. About everything. Resignations, announcements, all are meaningless, only results will now matter. This company has been around over 15 years. More than long enough to accomplish something. These guys, for whatever reason, have no credibility. I believe that steps are being taken that might establish credibility but until that is accomplished nothing written here will matter, nor will anything else. No substantial investor or institution will touch this tarnished child, without a new reason, and the biggest supporters are tired. I know I am. While I'm excited about the published results of the TNT trials I'm concerned about the complete absence of news regarding LYM-1. Is it because no one wants to license the drug or because Legere now owns it? Any opinions?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next